Heron Therapeutics (NASDAQ:HRTX) Raised to “Buy” at StockNews.com

Heron Therapeutics (NASDAQ:HRTX) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Separately, Needham & Company LLC cut their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday.

Heron Therapeutics Stock Down 5.5 %

NASDAQ HRTX traded down $0.07 during trading on Wednesday, hitting $1.21. The stock had a trading volume of 2,835,523 shares, compared to its average volume of 2,422,263. The company has a market capitalization of $183.52 million, a PE ratio of -6.72 and a beta of 1.81. Heron Therapeutics has a twelve month low of $0.53 and a twelve month high of $3.93. The firm has a 50 day moving average price of $1.85 and a 200 day moving average price of $2.53.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period in the previous year, the firm earned ($0.17) earnings per share. On average, sell-side analysts anticipate that Heron Therapeutics will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HRTX. nVerses Capital LLC purchased a new position in shares of Heron Therapeutics during the 2nd quarter worth $27,000. HB Wealth Management LLC purchased a new position in Heron Therapeutics during the second quarter worth about $35,000. Headlands Technologies LLC acquired a new stake in Heron Therapeutics in the 1st quarter worth about $30,000. B. Riley Wealth Advisors Inc. purchased a new stake in Heron Therapeutics in the 2nd quarter valued at about $41,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Heron Therapeutics during the 1st quarter valued at about $32,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.